Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation

被引：0

作者：

Satoshi Ueshima ^{[1
]}

Daiki Hira ^{[1
]}

Sayana Matsuda ^{[2
]}

Rio Michihata ^{[6
]}

Yohei Tabuchi ^{[1
]}

Tomoya Ozawa ^{[1
]}

Hideki Itoh ^{[2
]}

Moritake Iguchi ^{[3
]}

Masaharu Akao ^{[3
]}

Takanori Aizawa ^{[7
]}

Asami Kashiwa ^{[4
]}

Satoshi Shizuta ^{[4
]}

Takeru Makiyama ^{[5
]}

Yoshihisa Nakagawa ^{[5
]}

Minoru Horie ^{[8
]}

Tomohiro Terada ^{[5
]}

Toshiya Katsura ^{[5
]}

机构：

[1] Ritsumeikan University,College of Pharmaceutical Sciences

[2] Shiga University of Medical Science Hospital,Department of Pharmacy

[3] Shiga University of Medical Science,Department of Cardiovascular Medicine

[4] Seta Tsukinowa-Cho,Department of Cardiology

[5] National Hospital Organization Kyoto Medical Center,Department of Cardiovascular Medicine

[6] Kyoto University Graduate School of Medicine,Department of Clinical Pharmacology and Therapeutics

[7] Kyoto University Hospital,Division of Patient Safety

[8] Hiroshima University Hospital,Department of Cardiology

[9] Niigata City General Hospital,undefined

来源：

Journal of Pharmaceutical Health Care and Sciences | / 11卷 / 1期

关键词：

Edoxaban; Pharmacokinetics; Pharmacogenomics; Non-linear mixed-effects modeling; Atrial fibrillation;

D O I：

10.1186/s40780-025-00453-2

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment
Shimizu, Takako
Tachibana, Masaya
Kimura, Tetsuya
Kumakura, Tomohiko
Yoshihara, Kazutaka
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (05): : 484 - 491
[2] Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation
Ueshima, Satoshi
Hira, Daiki
Kimura, Yuuma
Fujii, Ryo
Tomitsuka, Chiho
Yamane, Takuya
Tabuchi, Yohei
Ozawa, Tomoya
Itoh, Hideki
Ohno, Seiko
Horie, Minoru
Terada, Tomohiro
Katsura, Toshiya
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1301 - 1312
[3] The safety of edoxaban for treating atrial fibrillation
Hammwoehner, Matthias
Goette, Andreas
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (11) : 1295 - 1303
[4] Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation
Aronow, Wilbert S.
Shamliyan, Tatyana A.
AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (03) : E270 - E285
[5] Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation
Ophelia Q. P. Yin
Kimura Tetsuya
Raymond Miller
European Journal of Clinical Pharmacology, 2014, 70 : 1339 - 1351
[6] Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation
Yin, Ophelia Q. P.
Tetsuya, Kimura
Miller, Raymond
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (11) : 1339 - 1351
[7] Edoxaban in the patient with atrial fibrillation and cancer
Maurea, Nicola
Riva, Letizia
GIORNALE ITALIANO DI CARDIOLOGIA, 2018, 19 (09) : 13S - 19S
[8] Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
Lin, Shin-Yi
Kuo, Ching-Hua
Ho, Li-Ting
Liu, Yen-Bin
Huang, Chih-Fen
Tang, Sung-Chun
Jeng, Jiann-Shing
FRONTIERS IN PHARMACOLOGY, 2021, 12
[9] Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation
Weitz, Jeffrey I.
Eikelboom, John
THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 257 - 270
[10] Edoxaban for the prevention of stroke in patients with atrial fibrillation
Escobar Cervantes, Carlos
Luis Merino, Jose
Barrios, Vivencio
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (04) : 319 - 330

← 1 2 3 4 5 →